Recall StatusTerminated
Date Initiated2016-12-27
Date Terminated2017-04-28
Product Quantity17,139 units
Reason for Recall
Endologix updated the Instructions for Use (IFU) and implemented modifications to the AFX Endovascular
AAA System (AFX System).
Firm Action
A Dear Physician letter dated 6/2/15 was sent to customers to inform them of the 2014 Clinical Update on the Endologix Endovascular Systems for AAA Repair. The letter provided update on the clinical programs and commercial experience (i.e., post-market surveillance).
On January 2016, a Dear Physician letter was sent to customers to inform them of the 2015 Clinical Update covering the Endologix Endovascular Systems for AAA Repair. The letter provided update reports for the cumulative clinical data and commercial experience (i.e., post-market surveillance) of the Powerlink System and the AFX Endovascular AAA system and contains important information and recommendations regarding the continued safe
and effective use of the devices.
On 12/27/2016 a Dear Physician letter provides important information related to the AFX Endovascular AAA System (AFX System). The letter informs the customers that a series of updates to the Instructions for Use (IFU) and modifications to the product were implemented, including introduction of a graft material processing improvement known as Duraply. Customers with any questions are instructed to contact their Endologix representative.
Root Cause
Under Investigation by firm
Distribution Pattern
US, and worldwide:
Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom.
Official Source
View FDA Recall →Source: FDA Enforcement Report / Recall database. Always confirm against the official FDA record.